Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.
Ola Landgren, MD, PhD
Advertisement
Ola Landgren, MD, PhD, is the chief of the myeloma division and leader of the experimental therapeutics program at Sylvester Comprehensive Cancer Center at the University of Miami Health System. He is also a professor of medicine at the University of Miami.
Articles by Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.
Ahead of the 30th European Hematology Association (EHA) Congress in Milan, Ola Landgren, MD, PhD, shares what he is most looking forward to and reflects on key advancements and ongoing challenges in hematology.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5